On June 14, 2026, Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) revealed at the 31st Congress of the European Hematology Association (EHA2026) in Stockholm, Sweden, updates on seventeen clinical trials of its core assets, with eight presented as posters. The data included findings from ongoing studies of olverembatinib (HQP1351), the initial third-generation BCR-ABL1 inhibitor sanctioned in China, and lisaftoclax (APG-2575), the primary Bcl-2 selective inhibitor of Chinese origin. This global, commercial-stage biopharmaceutical firm focuses on developing innovative therapies to cater to unmet needs in cancer treatment.